OncoMatch/Clinical Trials/NCT05020912
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
Is NCT05020912 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ALA for basal cell carcinoma.
Treatment: ALA — The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prior therapy
Cannot have received: medical or radiation therapy for other cancers
Currently being treated for other cancers with medical or radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cleveland Clinic, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify